Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Betty Yao

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Current Topics in Behavioral Neurosciences|November 25, 2010
Endocannabinoid receptor pharmacologyBetty Yao, Ken Mackie
Current Oncology (Toronto, Ont.)|May 26, 2023
Pediatric Brain Tumours: Lessons from the Immune MicroenvironmentBetty Yao, Alberto Delaidelli, Hannes Vogel, et al.
Assay and Drug Development Technologies|September 26, 2012
Development and validation of a medium-throughput electrophysiological assay for KCNQ2/3 channel openers using QPatch HTXu-Feng Zhang, Di Zhang, Carol S Surowy, et al.
Nature Communications|September 28, 2013
Species differences and molecular determinant of TRPA1 cold sensitivityJun Chen, Dawon Kang, Jing Xu, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 19, 2016
High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infectionFred Poordad, Charles S Landis, Armen Asatryan, et al.
Current Drug Safety|March 20, 2012
Negative inotropic effect of a CB2 agonist A-955840 in isolated rabbit ventricular myocytes is independent of CB1 and CB2 receptorsZhi Su, Lee Preusser, Gilbert Diaz, et al.
Antimicrobial Agents and Chemotherapy|December 30, 2015
Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 InfectionEric J Lawitz, William D O'Riordan, Armen Asatryan, et al.
Viruses|August 30, 2018
Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 InfectionTeresa I Ng, Tami Pilot-Matias, Rakesh Tripathi, et al.
NPJ Precision Oncology|July 24, 2025
Molecular subtyping of endometrial carcinoma cell lines uncovers subtype-specific targetable vulnerabilitiesEunice S Li, Rebecca Ho, Ran Tao, et al.
Bioorganic & Medicinal Chemistry Letters|February 29, 2012
Synthesis and evaluation of 2-amido-3-carboxamide thiophene CB₂ receptor agonists for pain managementDerek W Nelson, Jennifer M Frost, Karin R Tietje, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Current Topics in Behavioral Neurosciences|November 25, 2010
Endocannabinoid receptor pharmacologyBetty Yao, Ken Mackie
Current Oncology (Toronto, Ont.)|May 26, 2023
Pediatric Brain Tumours: Lessons from the Immune MicroenvironmentBetty Yao, Alberto Delaidelli, Hannes Vogel, et al.
Assay and Drug Development Technologies|September 26, 2012
Development and validation of a medium-throughput electrophysiological assay for KCNQ2/3 channel openers using QPatch HTXu-Feng Zhang, Di Zhang, Carol S Surowy, et al.
Nature Communications|September 28, 2013
Species differences and molecular determinant of TRPA1 cold sensitivityJun Chen, Dawon Kang, Jing Xu, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 19, 2016
High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infectionFred Poordad, Charles S Landis, Armen Asatryan, et al.
Current Drug Safety|March 20, 2012
Negative inotropic effect of a CB2 agonist A-955840 in isolated rabbit ventricular myocytes is independent of CB1 and CB2 receptorsZhi Su, Lee Preusser, Gilbert Diaz, et al.
Antimicrobial Agents and Chemotherapy|December 30, 2015
Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 InfectionEric J Lawitz, William D O'Riordan, Armen Asatryan, et al.
Viruses|August 30, 2018
Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 InfectionTeresa I Ng, Tami Pilot-Matias, Rakesh Tripathi, et al.
NPJ Precision Oncology|July 24, 2025
Molecular subtyping of endometrial carcinoma cell lines uncovers subtype-specific targetable vulnerabilitiesEunice S Li, Rebecca Ho, Ran Tao, et al.
Bioorganic & Medicinal Chemistry Letters|February 29, 2012
Synthesis and evaluation of 2-amido-3-carboxamide thiophene CB₂ receptor agonists for pain managementDerek W Nelson, Jennifer M Frost, Karin R Tietje, et al.
Pageof 1